Results 91 to 100 of about 3,797 (192)

Avances en hepatitis C

Revista del Hospital Italiano de Buenos Aires
La hepatitis C es la principal causa de hepatitis crónica, cirrosis y cáncer de hígado, así como la indicación más común de trasplante hepático en la Argentina y muchos otros países.
Ezequiel Mauro, Sebastián Marciano, Omar Galdame, Adrián Gadano   +3 more
doaj  

Ring-Closing Metathesis on Commercial Scale: Synthesis of HCV Protease Inhibitor Simeprevir

, 2019
The key macrocyclization step in the synthesis of simeprevir, a hepatitis C virus (HCV) antiviral drug, was studied. N-Boc substitution on the diene precursor changes the site of insertion of the metathesis catalyst and, consequently, the kinetic model ...
Dirk Van Den Heuvel (6369197), Jef Cuypers (6369191), Wouter Couck (6369194), András Horváth, Grégori Binot (6369188), Dominique Depré (3818533), Wim A. A. Vermeulen, Jef Cuypers, Wouter Couck, Syuzanna R. Harutyunyan (2534917), Stijn L. Wuyts (6369185), Stijn L. Wuyts, Dirk Van Den Heuvel, Syuzanna R. Harutyunyan, András Horváth (6369182), Wim A. A. Vermeulen (12332692), Grégori Binot, Dominique Depré   +17 more
core   +1 more source

Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review

Canadian Journal of Gastroenterology and Hepatology, 2014
Between 2001 and 2011, the standard of care for chronic hepatitis C virus (HCV) infection was a combination of pegylated interferon (PEGIFN) and ribavirin (RBV).
Alan Hoi Lun Yau, Eric M Yoshida
doaj   +1 more source

Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

, 2016
The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and ...
Lucia Fondacaro, V. Giannelli, Ialongo, P, R. Sacco, M. Marignani, C. F. Perno, Antonio Izzi, Messina, V, Sacco, R, Valerio Giannelli, Pellicelli, AM, MESSINA, VALERIA, M. Siciliano, P. Tarquini, Scifo, G, Ettorre, Gm, Moretti, A, D'Ambrosio, C, Carlo F. Perno, Ceccherini-Silberstein, F, Francesca Ceccherini‐Silberstein, Massimo Marignani, Giuseppe M. Ettorre, D'AMBROSIO, CLAUDIO, Marignani, M, A. Izzi, Cecilia D'Ambrosio, Giannelli, V, Adriano M. Pellicelli, Izzi, A, Barbarini, G, SACCO, ROBERTO, V. Pace Palitti, Pasquale Ialongo, Gaetano Scifo, P. Vignally, Tarquini, P, Siciliano, M, A. M. Pellicelli, Pierluigi Tarquini, Vignally, P, G. Scifo, G. Barbarini, Alessandra Moretti, Giorgio Barbarini, L. Fondacaro, G. M. Ettorre, Vincenzo Messina, F. Ceccherini-Silberstein, P. Ialongo, Ascione, A, PERNO, CARLO FEDERICO, Fondacaro, L, C. D'Ambrosio, CECCHERINI SILBERSTEIN, FRANCESCA, Barbarini, G., Valeria Pace Palitti, Pascal Vignally, Massimo Siciliano, Antonio Ascione, Perno, CF, Pace Palitti, V, A. Ascione, A. Moretti, IZZI, ALESSANDRO, V. Messina, Rodolfo Sacco   +66 more
core   +1 more source

Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study

, 2017
This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus (HCV) genotype 1 postorthotopic liver transplant evaluated once-daily simeprevir 150 mg + sofosbuvir 400 mg, with and without ribavirin 1000 mg. Primary endpoint was
Brown, Robert S, Muir, Andrew, Burton, James R, Reddy, Rajender, Rabinovitz, Mordechai, Ryan, Robert, Prabhakar, Avinash, Brown, Kimberly A, Villadiego, Shirley, Shprecher, Adam, Firpi-Morell, Roberto, O\u27Brien, Christopher, Fontana, Robert J, O\u27Leary, Jacqueline G   +13 more
core  

Analytical Profile of Antiviral Drugs-Remdesivir, Simeprevir, and Sofosbuvir: A Review [PDF]

Remdesivir (RDV) is an antiviral drug and a phosphonamidite prodrug designed to have activity against a broad spectrum of viruses, act as a nucleoside analogue, and inhibit the RNA-dependent RNA polymerase [RDRP] of coronaviruses, including SARS-CoV-2 ...
Sravya, K., Sri, G. Ramya, Eswarudu, M.M., Krishna, P. Siva, Babu, P. Srinivasa, Vikhil, J.   +5 more
core   +1 more source

Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil

Brazilian Journal of Infectious Diseases
Background This study aimed to evaluate the clinical effectiveness in terms of sustained virological response and tolerability of available second generation direct-acting antivirals in Brazilian patients.
Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba, Astrid Wiens, Maria Lucia Alves Pedroso, Vanessa Ferreira de Camargo Radunz, Cláudia Alexandra Pontes Ivantes, Aline Satie Oba Kuniyoshi, Roberto Pontarolo   +7 more
doaj   +1 more source

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): A randomised, double-blind, non-inferiority phase 3 trial

, 2015
Background: We did a phase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and compensated liver disease that related to the standard of care for these patients at the time this study was initiated.
Reddy K Rajender, Verbinnen, Thierry, Dammers, Elisabeth, George Jacob, Kurland, Darryl, ANDREONE, PIETRO, Andreone Pietro, Jessner, Wolfgang, Scott, Jane, Verbinnen Thierry, Reddy, K. Rajender, Weiland Ola, Zeuzem Stefan, Zoulim Fabien, Horban Andrzej, Stanciu, Carol, Horban, Andrzej, Villamil, Federico Guillermo, Jessner Wolfgang, Scott Jane, Kurland Darryl, Weiland, Ola, Lenz, Oliver, Ouwerkerk-Mahadevan Sivi, Ouwerkerk Mahadevan, Sivi, Zoulim, Fabien, Stanciu Carol, Dammers Elisabeth, Fu Min, Fu, Min, Villamil Federico Guillermo, George, Jacob, Lenz Oliver, Zeuzem, Stefan   +33 more
core   +1 more source

Simeprevir [PDF]

, 2020
openaire   +1 more source

Sofosbuvir and Simeprevir Combination Therapy for HCV Genotype 1 Infection: Results of a Single-Center VA Experience.

, 2016
Treatment of chronic hepatitis C virus (HCV) infection remains a priority in the veterans affairs (VA) health care system nationwide, as there is a high burden of liver disease due to HCV infection among US veterans.
Vance, Evan, Youtseff, Helen, Antoine, Marie, Jeffers, Lennox J, Toro, Maribel, Peyton, Adam, DO, Hernandez, Maria Del Pilar, Gilinski, Dani, Sclair, Seth N   +8 more
core   +1 more source